InnoCare Pharma’s next-generation TRK inhibitor zurletrectinib gets China NMPA approval to treat NTRK fusion-positive tumours: Beijing Saturday, December 13, 2025, 16:30 Hrs [IS ...
OTR Therapeutics and Zealand Pharma ink license agreement to develop novel therapeutics for metabolic diseases: Shanghai Saturday, December 13, 2025, 16:00 Hrs [IST] OTR Therapeut ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback